Jose I Borrell
Overview
Explore the profile of Jose I Borrell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dulsat J, Puig de la Bellacasa R, Borrell J
Molecules
. 2025 Jan;
29(24.
PMID: 39770130
In cases in which a rapid metabolism is the cause of an unfavorable pharmacokinetic profile, it is important to determine the Sites of Metabolism (SoMs) of a molecule to introduce...
2.
Martinez-Asensio M, Sarrias L, Gorjon-de-Pablo G, Fernandez-Serrano M, Camalo-Vila J, Gibert A, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273392
The identification of new compounds with potential activity against CXC chemokine receptor type 4 (CXCR4) has been broadly studied, implying several chemical families, particularly AMD3100 derivatives. Molecular modeling has played...
3.
Manen-Freixa L, Moliner-Cubel S, Gamo F, Crespo B, Borrell J, Teixido J, et al.
Bioorg Chem
. 2024 May;
148:107472.
PMID: 38788364
Patents tend to define a huge chemical space described by the combinatorial nature of Markush structures. However, the optimization of new principal active ingredient is frequently driven by a simple...
4.
de Rocafiguera C, Belsa B, Font-Bardia M, Puigjaner C, Serra E, Cuartero-Albesa A, et al.
Pharmaceuticals (Basel)
. 2024 Mar;
17(3).
PMID: 38543069
The impact of the crystalline or amorphous structure of a solid on the solubility and pharmacokinetic properties of a drug candidate is always considered by the pharmaceutical industry during the...
5.
Donaire-Arias A, Poulsen M, Ramon-Costa J, Montagut A, Estrada-Tejedor R, Borrell J
Molecules
. 2023 Nov;
28(22).
PMID: 38005298
Chalcones are a type of molecule that can be considered as easily synthesizable through aldol condensation or that can be readily purchased from habitual commercial vendors. However, on reviewing the...
6.
Dulsat J, Lopez-Nieto B, Estrada-Tejedor R, Borrell J
Molecules
. 2023 Jan;
28(2).
PMID: 36677832
For a new molecular entity (NME) to become a drug, it is not only essential to have the right biological activity also be safe and efficient, but it is also...
7.
Deconstructing Markush: Improving the R&D Efficiency Using Library Selection in Early Drug Discovery
Manen-Freixa L, Borrell J, Teixido J, Estrada-Tejedor R
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145380
Most of the product patents claim a large number of compounds based on a Markush structure. However, the identification and optimization of new principal active ingredients is frequently driven by...
8.
Bou-Petit E, Hummer S, Alarcon H, Slobodnyuk K, Cano-Galietero M, Fuentes P, et al.
J Med Chem
. 2022 Apr;
65(8):6070-6087.
PMID: 35417652
Targeting the kinases MNK1 and MNK2 has emerged as a valuable strategy in oncology. However, most of the advanced inhibitors are acting in an adenosine triphosphate (ATP)-competitive mode, precluding the...
9.
Donaire-Arias A, Montagut A, Puig de la Bellacasa R, Estrada-Tejedor R, Teixido J, Borrell J
Molecules
. 2022 Apr;
27(7).
PMID: 35408636
Pyrazolo[3,4-]pyridines are a group of heterocyclic compounds presenting two possible tautomeric forms: the 1- and 2-isomers. More than 300,000 1-pyrazolo[3,4-]pyridines have been described which are included in more than 5500...
10.
Masip V, Lirio A, Sanchez-Lopez A, Cuenca A, Puig de la Bellacasa R, Abrisqueta P, et al.
Pharmaceuticals (Basel)
. 2021 Dec;
14(12).
PMID: 34959711
Pyrido[2,3-]pyrimidin-7(8)-ones have attracted widespread interest due to their similarity with nitrogenous bases found in DNA and RNA and their potential applicability as tyrosine kinase inhibitors. Such structures, presenting up to...